Compare PAGSEG Inc (PAGS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? PAGSEG Inc trades at $10.79 (market cap $2.94B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 43.4× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PAGS | VRTX | |
|---|---|---|
Market Cap | $2.94B | $127.55B |
Volume | 4,242,708 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $12.00 | $557.96 |
52-Week Low | $8.44 | $407.37 |
Typical Hold Time | 26 Days | 120 Days |
Enterprise Value | $11.02B | $121.68B |
Dividend Yield | 10.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong profitability with a 10.45% net income margin and trades at a discounted valuation with a P/E of 7.1 and P/S of 0.74. Recent earnings beat expectations in Q2 2026, and a $0.28 dividend is scheduled for September 2026.
The outlook is positive given undervaluation, profitability, and dividend yield, but risks include a recent earnings miss in Q1 2026 and a projected negative net cash flow for 2026. Investor sentiment is supported by strong analyst buy ratings, though technical indicators show some overbought conditions with RSI at 78.08.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
